Fundraising Fox

K2 Biolabs

Houston, US · Founded 2021 · Delaware corporation · 1 known investors

k2-biolabs.com ↗

K2bio is a contract research organization offering in vivo study design, execution, and analysis in an AAALAC-accredited vivarium, along with in vitro research and pharmacology services for biotech and pharmaceutical partners. It also provides private lab spaces, benches, and scientific infrastructure for research teams in Houston's biotech hub.

BiotechHealthtech

Founders & leadership

AD
Andrew DeSommaMember of the Board of Directors
GF
Gerard FleuryMember of the Board of Directors
CJ
Clifford J. StocksMember of the Board of Directors
AS
Andrew StrongMember of the Board of Directors
DC
Daniel ClarkChief Financial Officer
KS
Kevin SlawinMember of the Board of Directors
KJ
Kieron JonesChief Executive Officer and Member of the Board of Directors

Investors · 1

Rapha Capital Management, LLCSurfsidevia Kevin M. Slawin · inferred

Competitors · 8

by search overlap
Concord Communications15 shared keywords
KALA BIO15 shared keywords
Mapquest14 shared keywordsProvider of geographical information systems and services; acquired by America Online.
Krystalbio13 shared keywordsKrystal Biotech develops and commercializes redosable gene therapies to treat severe, rare, and life-threatening diseases with limited or no approved treatments. Its first commercial product, VYJUVEK, is a redosable gene therapy for dystrophic epidermolysis bullosa.
Coya Therapeutics13 shared keywords
Korro Bio12 shared keywordsRNA-editing therapeutics company using its OPERA technology platform.
Ziprecruiter11 shared keywords
Built In10 shared keywords

Companies competing with K2 Biolabs for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements
▶$615.5KraisedAug 2023 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew DeSommaDirector
  • Gerard FleuryDirector
  • Clifford J. StocksDirector
  • Andrew StrongDirector
  • Daniel ClarkExecutive Officer
  • Kevin SlawinDirector
  • Kieron JonesDirector, Executive Officer
Offering amount
$3M
Amount sold
$615.5K
First sale
Jun 2023
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.5MraisedMar 2021 · 40 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • KIERON JONESExecutive Officer, Director
  • Andrew StrongDirector
  • Andrew DeSommaDirector
  • Kevin SlawinDirector
  • Clifford StocksDirector
Offering amount
$5.5M
Amount sold
$5.5M
Minimum investment
$25K
Proceeds to insiders
$270K
First sale
Mar 2021
Incorporated
Limited Liability Company, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.